Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Open Access
- 1 January 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 13 (1), 102
- https://doi.org/10.1186/1475-2840-13-102
Abstract
Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that any intervention to mitigate this risk must address CV risk factors beyond glycemia alone. The SGLT-2 inhibitor empagliflozin improves glucose control, body weight and blood pressure when used as monotherapy or add-on to other antihyperglycemic agents in patients with type 2 diabetes. The aim of the ongoing EMPA-REG OUTCOME™ trial is to determine the long-term CV safety of empagliflozin, as well as investigating potential benefits on macro-/microvascular outcomes.Keywords
This publication has 23 references indexed in Scilit:
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita miceAmerican Journal of Physiology-Renal Physiology, 2014
- Incorporating Lag Time to Benefit Into Prevention Decisions for Older AdultsJAMA, 2013
- Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusPublished by Wiley ,2013
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 DiabetesDiabetes Care, 2013
- Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trialDiabetes, Obesity and Metabolism, 2013
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialThe Lancet, 2013
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trialDiabetes and Vascular Disease Research, 2013
- Maintaining confidentiality of interim data to enhance trial integrity and credibilityClinical Trials, 2008
- Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statementAmerican Heart Journal, 1991